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Women want multi-purpose technologies
(MPTs)
• Women worldwide face dual risks of
unintended pregnancy and HIV

• Risk of unintended pregnancy often
outweighs concerns about HIV
• 83% of women prefer HIV/STI
prevention products
with contraception vs. HIV/STI
prevention alone
Source: Plagianos et al. (2018) Abstract PO.93, HIV R4P Conference, Madrid, Spain, 21–25 October

Dual prevention pill (DPP)

• Delivery system: oral pill
• APIs: Combines 2 approved drugs (Oral contraceptive and HIV PrEP)
• Create a single product that combines a 28-day oral contraceptive
regimen with oral PrEP

5.4 million HIV-negative COC users in
15 sub-Saharan African countries
HIV-negative COC
users, AGYW
15–24 years old

1.27
million
4.13
million

HIV-negative
COC users,
25–49 years old

Potentially a 2- to 10-fold increase in PrEP
usage
Estimated DPP users compared to current PrEP users
Current PrEP users (women and men)

Estimated DPP users
1,252,000

513,000
250,000
113,000
Low range conversion estimate

113,000
Mid-range conversion estimate

113,000
High range conversion estimate

Begg, L. et al. (2021) “Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake,” BMJ Sex Reprod
Health. 47: 166–172. doi:10.1136/bmjsrh-2020-200662

Considerations
for the DPP and
new biomedical
technologies

Friedland, B., S. Mathur, L. B. Haddad. 2021. The promise of the dual
prevention pill: A framework for development and introduction. Front.
Reprod. Health. 3:682689 doi: 10.3389/frph.2021.682689

While nearly all AGYW were eligible for
PrEP, more need access to it
Engaged in HIV prev programming

154

PrEP eligible
289

PrEP consultations
272

139
112

34

Adolescent girls

Young women

Study site: Kenya
Heck, C, S. Mathur, H. Alwang'a, D. Oluoch-Madiang’, R. Obanda, M. Owiti, J. Okal. Oral PrEP consultations among adolescent girls and young women in Kisumu
County, Kenya: Insights from the DREAMS Program. Under review at AIDS and Behavior.

Health care provider perspectives &
access to PrEP
Factors associated with providers’
willingness to prescribe PrEP (n=316)

Negative attitudes toward
AGYW sexuality
Behavioral disinhibition
scale

Adj. IRR1
(95% CI)
0.81
(0.66–0.99)*
0.89
(0.79–0.99)*

Some of us are very critical and
judgmental. We just judge
someone, ‘Ooh you came again?
Last time you had gonorrhea, did
you do it again?’
—Service provider, age 32, TZ

1Adjusted

for provider demographics, prior PrEP knowledge, other facility
factors (e.g., stockouts)
*p<0.05

Study site: Tanzania
Pilgrim N, Jani N, Mathur S, Kahabuka C, Saria V, Makyao N, Apicella L, Pulerwitz J. (2018) “Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The
role of provider biases and quality of care,” PLoS ONE 13(4): e0196280. doi: 10.1371/journal.pone.0196280

Partnership dynamics &
influence on PrEP use
Our relationship will be affected if he is
not informed…if he understands me
properly, he can decide to accompany
me and begin to take PrEP as well. But
if I don’t tell him and he finds them on
his own, that is where the problem
steps in.
—Young woman, Tanzania

…he [partner] came across those drugs, and
he got out of control...when he found the
drugs he became disturbed, furious, threw
them, asked me whether a I am a
commercial sex worker, whether am
infected, if I had infected him. I told him the
drugs are not for HIV, fearing to explain
further, …He beat me to tell him the truth….
He beat me and we seriously fought….
—Young woman, PrEP user (8mo), Uganda

Jani, N., S. Mathur, C. Kahabuka, N. Makyao, N. Pilgrim. 2021. Relationship dynamics and anticipated stigma: Key considerations for PrEP use among Tanzanian adolescent girls
and young women and male partners. PLoS ONE 16(2): e0246717. doi: 10.1371/journal.pone.0246717
Mathur, S, G Mirembe, J. Nanyondo, W. Nansalire, D. Kibirige, J. Matheka, B. Mwesigwa, A. Tindikahwa, F. Kiweewa, M. Millard, E. Akom, H. Kibuuka. 2020. "Side effects, life
transitions, and disclosure: reasons for oral pre-exposure prophylaxis (PrEP) discontinuation among young women engaged in sex work in Uganda (PEC0602)." Poster presented
at AIDS 2020, San Francisco, CA, USA, 6–10 July.

DPP Acceptability Studies (2019-2023)
Qualitative formative research
to explore acceptability of DPP
to increase PrEP uptake.

Among CURRENT COC USERS,
compare preference,
adherence, and acceptability of
a single DPP capsule to two
separate tablets (COC and
PrEP).

Focus groups with end-users
(COC and non-COC users)

In-depth interviews with different cadre of
family planning and HIV health care providers

Randomized, crossover clinical trials
•

•

Zimbabwe: 30 AGYW (16-24 yrs)

South Africa: 96 women (16-40 yrs)
Choice period (South Africa)

In-depth interviews with women who withdraw
early plus sub-set of completers

Perceived benefits of the DPP
• Empower women to access HIV and pregnancy prevention they can
control themselves
•
•
•
•

Prevent school dropout in young women due to unplanned pregnancies
Protect against stealthing (removal of condom during sex without consent)
Provide protection during spontaneous sexual activity (condom access limited)
Offer protection in the event of rape

• Reduce frequency of clinic visits for women currently using both PrEP
and COCs
• Lessen the burden of taking two separate pills
• Positively impact contraception and PrEP uptake
Source: n = 14 FGDs with age 16–40 from South Africa and Zimbabwe
Source: n = 29 health care providers from South Africa and Zimbabwe

Potential challenges for DPP
Product

• Side effects (double the
side effects?)
• Daily dosing
• Duration of use

Service delivery

Social

• Provider attitudes
• Waiting period/testing
requirements
• Provision outside the
facility
• Counseling tools to
encourage informed choice
• Counseling for effective
use
• Cost/ability to afford DPP

• Partner approval
• Family and community
leaders unsupportive of
PrEP and/or COC use
• Myths and
misconceptions around
COCs
• HIV-related stigma
• Sociocultural norms and
taboos regarding
adolescent sexual behavior

Source: n = 14 FGDs with age 16–40 from South Africa and Zimbabwe
Source: n = 29 health care providers from South Africa and Zimbabwe

Summary
• DPP potentially the fastest MPT to market
• May overcome uptake and adherence barriers of oral PrEP
• Potential to expand contraceptive choice
• Key to assess integration and implementation challenges early in
the product development lifecycle

Acknowledgements
Study Participants
Population Council, DREAMS Implementation
Science Research Team, USA, Kenya and
Tanzania: Sanyukta Mathur, Jerry Okal, Nanlesta
Pilgrim, Nrupa Jani, Craig J. Heck, James
Matheka, Lou Apicella, Julie Pulerwitz
Kenya: Collaboration with DREAMS implementing
partners (PATH/Aphia Plus) & local USAID and
PEPFAR DREAMS teams
Tanzania: Local implementing partner—CSK
(Catherine Kahabuka), Neema Makyao (NACP,
Tanzania) & collaboration with NACP/MOH and
local USAID and PEPFAR DREAMS teams
Funding support for the DREAMS studies from
the Bill & Melinda Gates Foundation

Population Council, DPP Acceptability study
team: Barbara Friedland, Sanyukta Mathur, Tracy
McClair, Lorna Begg, Marlena Plagianos,
Rebecca Brodsky, Bruce Variano,
Loreley Villamide-Herrera, Susanna Grecky, Dan
Loven, Thierry Bonnaire, Brady Zieman, Lisa
Haddad

Funding support for the DPP studies from

Wits RHI, Johannesburg, South Africa: Thesla
Palanee Phillips, Krishnaveni Reddy, Lebogang
Maila, Onthatile Maboa, Lydia Mampuru, Siyanda
Tenza, & Wits RHI Staff
UZ-CTRC, Harare, Zimbabwe: Nyaradzo Mgodi,
Petina Musara, Adlight Dandadzi, Prisca Mutero,
Lucy Godo, Terrance Kufakunesu, Natasha
Sedze, Caroline Murombedzi, & Zengeza CRS
Staff

This presentation is made possible by the generous support of the American people
through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and U.S. Agency for
International Development (USAID). The contents are the responsibility of the authors and
do not necessarily reflect the views of PEPFAR, USAID, or the U.S. Government.
Research reported in this publication was also supported by the National Institute of
Mental Health of the National Institutes of Health under Award Number R34MH119982.
The content is solely the responsibility of the authors and does not necessarily represent
the official views of the National Institutes of Health.

© 2021 The Population Council. All rights reserved.
Use of these materials is permitted only for noncommercial purposes.
The following full source citation must be included:
Mathur, Sanyukta. 2021. “The Promise of the Dual Prevention Pill,” presented at virtual webinar “Can Fantasies
Become Realties? The Quest for Multi-purpose Prevention Products,” AIDS Foundation of Chicago, 13 October.

This presentation may contain materials owned by others. User is responsible for obtaining permissions for use from
third parties as needed.

